Cn Immunotech develops next‑generation T‑cell therapies using its proprietary STAR‑T and enTCR‑T platforms, which enable precise receptor engineering, enhanced tumor infiltration, and multiplexed antigen targeting. The company offers modular, non‑viral gene delivery and GMP‑compatible manufacturing to accelerate preclinical and clinical development for hematologic cancers, solid tumors, and viral infections, serving pharma, biotech, and academic partners.
Funding
Funding not disclosed
Founders
Product
Problem
Current immunotherapy approaches, such as CAR‑T cells, show limited efficacy against solid tumors and certain viral infections, and the development pipeline for novel T‑cell therapies is constrained by complex engineering and manufacturing processes.
Solution
Cn Immunotech leverages two proprietary T‑cell engineering platforms—STAR‑T and enTCR‑T—to generate next‑generation cellular therapeutics that can target a broad spectrum of hematologic malignancies, solid tumors, and viral diseases. The platforms enable precise receptor design and functional optimization to improve tumor infiltration, persistence, and antigen specificity. By integrating advanced gene editing and scalable manufacturing workflows, the company accelerates preclinical validation and clinical translation of its pipeline candidates. Collaborative partnerships with pharmaceutical and biotech firms allow rapid integration of these engineered T‑cell products into existing development programs, expanding therapeutic options for patients with unmet medical needs.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to develop or augment T‑cell‑based therapies for oncology and infectious disease indications, as well as academic research groups focused on cellular immunotherapy.
Features
- STAR‑T platform for constructing synthetic T‑cell receptors with enhanced affinity and signaling control
- enTCR‑T platform that combines engineered T‑cell receptors with safety switches and multiplexed antigen targeting
- Modular vector architecture supporting rapid swapping of antigen-binding domains for diverse disease targets
- Optimized non‑viral gene delivery and GMP‑compatible manufacturing processes to reduce production time and cost
- Integrated preclinical screening pipeline including in‑vivo tumor models and viral infection assays